CARLSMED, INC.

Signal Note: OrbiMed Entry into CARL

OrbiMed's $15.5M initiation in Carlsbad Medical Devices signals conviction in the company's core orthopedic/spine portfolio, likely driven by near-term regulatory catalysts or commercial traction in their minimally invasive surgical platforms. This establishes a meaningful institutional anchor given OrbiMed's track record of early-stage conviction bets that typically precede inflection events. Monitor for 510(k) clearances, clinical trial readouts, or revenue guidance updates within 6-12 months as key validation points.